ABBOTT PARK, Ill., Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA(R) (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease. This announcement follows FDA approval for the Crohn's disease indication, which Abbott received in February, and is the fourth approved indication for HUMIRA in the United States and the European Union.
Crohn's disease is a serious, chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than 1 million people in North America and Europe. It affects people of all ages, but it is primarily a disease of young adults, with onset typically before age 40. There is no medical or surgical cure for Crohn's disease and few treatment options exist for patients suffering with this chronic condition.
"Crohn's can have a devastating impact on patients, many of whom are young and active, making it difficult to carry out normal day-to-day activities," said Rod Mitchell, chairman, European Federation of Crohn's & Ulcerative Colitis Associations. "The unpredictable nature of the disease can seriously impact their quality of life and self-esteem. For the half million people across Europe suffering from Crohn's, this approval offers hope to help them regain control of their disease."
Common symptoms of Crohn's disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, fistulas (ulcers that form tunnels to surrounding tissues), and malnutrition. Over the course of their disease, as many as 75 percent of patients with Crohn's disease will undergo surgery at least once for complications or disease resistant to treatment. Of thosPage: 1 2 Related medicine news :1
. Approval for DNA test to detect cystic fibrosis
. Vaccine For Cervical Cancer Awaits Approval3
. WHO Gives Its Approval For Bird Flu Test Kit4
. FDA Gives Its Approval For Inhaler5
. RotaTeq Gets US Approval6
. Better Communication With FDA Could Speed Up Approval Of New Drugs7
. Nerve Stimulator for Depression Though Not Effective Was Given Approval8
. Ranbaxy Gets USFDA Approval For Doxycycline Tablets9
. Global Education Net Pvt Medical College Gets MCI Approval10
. Approval of Drugs for the Treatment of Late-Stage Cancer11
. Lupin Gets USFDA Approval For Quinapril Tablets